Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene
Open Access
- 15 February 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (2) , e0192602
Abstract
Anti-HCMV treatments used in immunosuppressed patients reduce viral replication, but resistant viral strains can emerge. Moreover, these drugs do not target latently infected cells. We designed two anti-viral CRISPR/Cas9 strategies to target the UL122/123 gene, a key regulator of lytic replication and reactivation from latency. The singleplex strategy contains one gRNA to target the start codon. The multiplex strategy contains three gRNAs to excise the complete UL122/123 gene. Primary fibroblasts and U-251 MG cells were transduced with lentiviral vectors encoding Cas9 and one or three gRNAs. Both strategies induced mutations in the target gene and a concomitant reduction of immediate early (IE) protein expression in primary fibroblasts. Further detailed analysis in U-251 MG cells showed that the singleplex strategy induced 50% of indels in the viral genome, leading to a reduction in IE protein expression. The multiplex strategy excised the IE gene in 90% of all viral genomes and thus led to the inhibition of IE protein expression. Consequently, viral genome replication and late protein expression were reduced by 90%. Finally, the production of new viral particles was nearly abrogated. In conclusion, the multiplex anti-UL122/123 CRISPR/Cas9 system can target the viral genome efficiently enough to significantly prevent viral replication.Keywords
Funding Information
- Agence Nationale de la Recherche (FR) (ANR-11-LABX-0016-01)
- Fondation Centaure
- European Society of Clinical Microbiology and Infectious Diseases
- European Society of Organ Transplantation
This publication has 51 references indexed in Scilit:
- Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirusScientific Reports, 2013
- DNA targeting specificity of RNA-guided Cas9 nucleasesNature Biotechnology, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Cytomegalovirus: pathogen, paradigm, and puzzleJournal of Clinical Investigation, 2011
- Immunobiology of Human Cytomegalovirus: from Bench to BedsideClinical Microbiology Reviews, 2009
- Regulation of the Transcription and Replication Cycle of Human Cytomegalovirus Is Insensitive to Genetic Elimination of the Cognate NF-κB Binding Sites in the EnhancerJournal of Virology, 2006
- Antiviral drugs for cytomegalovirus diseasesAntiviral Research, 2006
- Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of ActionAntimicrobial Agents and Chemotherapy, 2002
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991
- Comparison of human cytomegalovirus growth in MRC‐5 human fibroblasts, brain, and choroid plexus cells in vitroJournal of Medical Virology, 1981